Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Choroidal Neovascularization - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
Choroidal Neovascularization Pipeline Insight, 2024 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization market. A detailed picture of the Choroidal Neovascularization pipeline landscape is provided, which includes the disease overview and Choroidal Neovascularization treatment guidelines.
The assessment part of the report embraces in-depth Choroidal Neovascularization commercial assessment and clinical assessment of the Choroidal Neovascularization pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Choroidal Neovascularization collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Choroidal Neovascularization Analytical Perspective
In-depth Choroidal Neovascularization Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Choroidal Neovascularization Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Choroidal Neovascularization of Pipeline Development Activities
- All of the companies that are developing therapies for the treatment of Choroidal Neovascularization with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Choroidal Neovascularization treatment.
- Choroidal Neovascularization key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Choroidal Neovascularization market.
Key Topics Covered:
1. Report Introduction
2. Choroidal Neovascularization
2.1. Overview
2.2. History
2.3. Choroidal Neovascularization Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Choroidal Neovascularization Diagnosis
2.6.1. Diagnostic Guidelines
3. Choroidal Neovascularization Current Treatment Patterns
3.1. Choroidal Neovascularization Treatment Guidelines
4. Choroidal Neovascularization - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Choroidal Neovascularization companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Choroidal Neovascularization Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Choroidal Neovascularization Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Choroidal Neovascularization Late Stage Products (Phase-III)
7. Choroidal Neovascularization Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Choroidal Neovascularization Discontinued Products
13. Choroidal Neovascularization Product Profiles
Detailed information in the report
14. Choroidal Neovascularization Key Companies
15. Choroidal Neovascularization Key Products
16. Dormant and Discontinued Products
17. Choroidal Neovascularization Unmet Needs
18. Choroidal Neovascularization Future Perspectives
19. Choroidal Neovascularization Analyst Review
20. Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1krv9y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
